TABLE 2.
Prescription Cost and Coverage by Copayment Status
| No Copay Amount (n = 3,091) | Some Copay Amount (n = 5,121) | Total (N = 8,212) | P Value | |
|---|---|---|---|---|
| Any PAP coverage, n (%) | 923 (29.9) | 28 (0.5) | 951 (11.6) | < 0.0001a |
| Primary insurance, n (%) | < 0.0001a | |||
| Missing | 15 (0.5) | 27 (0.5) | 42 (0.5) | |
| Cash | 1 (0.0) | 160 (3.1) | 161 (2.0) | |
| Commercial/Part D | 560 (18.1) | 2,858 (55.8) | 3,418 (41.6) | |
| Copay card | 21 (0.7) | 13 (0.3) | 34 (0.4) | |
| Grant/sponsor | 20 (0.6) | 126 (2.5) | 146 (1.8) | |
| International patient | 0 (0.0) | 6 (0.1) | 6 (0.1) | |
| Medicaid/Medicare B | 1,290 (41.7) | 517 (10.1) | 1,807 (22.0) | |
| Part D | 1,181 (38.2) | 1,410 (27.5) | 2,591 (31.6) | |
| VA benefits | 3 (0.1) | 4 (0.1) | 7 (0.1) | |
| Secondary insurance, n (%) | < 0.0001a | |||
| Missing | 1,974 (63.9) | 4,731 (92.4) | 6,705 (81.6) | |
| Cash | 14 (0.5) | 116 (2.3) | 130 (1.6) | |
| Commercial | 47 (1.5) | 87 (1.7) | 134 (1.6) | |
| Copay card | 38 (1.2) | 50 (1.0) | 88 (1.1) | |
| Grant/sponsor | 862 (27.9) | 7 (0.1) | 869 (10.6) | |
| Medicaid/Medicare B | 137 (4.4) | 118 (2.3) | 255 (3.1) | |
| None | 7 (0.2) | 0 (0.0) | 7 (0.1) | |
| Part D | 10 (0.3) | 11 (0.2) | 21 (0.3) | |
| Sickle cell program | 2 (0.1) | 1 (0.0) | 3 (0.0) | |
| PAP coverage, n (%) | < 0.0001b | |||
| 0% | 2,168 (70.1) | 5,093 (99.5) | 7,261 (88.4) | |
| 0%-25% | 806 (26.1) | 20 (0.4) | 826 (10.1) | |
| 25%-50% | 115 (3.7) | 3 (0.1) | 118 (1.4) | |
| 50%-75% | 1 (0.0) | 1 (0.0) | 2 (0.0) | |
| 75%-100% | 1 (0.0) | 4 (0.1) | 5 (0.1) | |
| Copay amount | ||||
| Mean (SD) | 148.5 (504.2) | |||
| Median | 20.0 | |||
| Quarter 1, Q3 | 10.0, 80.3 | |||
| Range | (0.0-9,928.5) | |||
| PAP | < 0.0001c | |||
| Mean (SD) | 193.6 (511.1) | 10.3 (271.0) | 79.3 (389.9) | |
| Median | 0.0 | 0.0 | 0.0 | |
| Q1, Q3 | 0.0, 194.0 | 0.0, 0.0 | 0.0, 0.0 | |
| Range | (0.0-3,432.2) | (0.0-12,288.1) | (0.0-12,288.1) | |
| What the cancer center was paid by the primary insurance | < 0.0001c | |||
| Mean (SD) | 4,610.1 (3,641.6) | 3,500.8 (4,017.1) | 3,918.3 (3,916.8) | |
| Median | 3,169.3 | 1,967.0 | 26,27.9 | |
| Q1, Q3 | 1,865.0, 7,692.3 | 33.0, 6,883.0 | 163.6, 7,307.7 | |
| Range | (4.3-21,805.2) | (0.0-28,090.3) | (0.0-28,090.3) | |
| Drug cash price at the cancer center | < 0.0001c | |||
| Mean (SD) | 4,837.9 (3,738.8) | 3,678.7 (4,121.9) | 4,115.0 (4,021.3) | |
| Median | 3,304.9 | 2,224.8 | 2,762.1 | |
| Q1, Q3 | 1,974.6, 8,119.6 | 57.1, 7,299.8 | 190.9, 7,698.3 | |
| Range | (6.0-21,805.2) | (1.6-28,140.3) | (1.6-28,140.3) | |
aChi-square test.
bFisher exact test.
cKruskal Wallis test.
PAP = patient financial assistance program; Q = quartile; SD = standard deviation; VA = Veterans Affairs.